analyst
IN
NASDAQ · INSM
Insmed Incorporated
Healthcare · Medical - Pharmaceuticals
$119.92
Down-$5.38 (-4.29%)
Updated Sep 16, 2026, 9:19 AM
SID Score
6.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 41.63B
- P/E ratio
- -34.92
- Dividend yield
- 0.00%
- 52-week range
- $90.39 – $212.75
- Volume
- 3.36M
- Avg. volume
- 2.37M
Price performance
INSM price history
1M range · 20 trading sessions · Daily adjusted prices
INSM closed at $119.92 after 20 trading sessions, down 6.65% for the selected period.
- Last close
- $119.92
- Period change
- -6.65%
- Period low
- $118.54
- Period high
- $130.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $126.10 | $126.10 | $118.34 | $119.92 | 3.36M |
| Sep 14, 2026 | $129.50 | $130.7783 | $124.58 | $125.30 | 1.61M |
| Sep 11, 2026 | $127.98 | $130.25 | $126.52 | $129.41 | 1.7M |
| Sep 10, 2026 | $127.22 | $128.85 | $124.29 | $127.28 | 2.59M |
| Sep 9, 2026 | $124.00 | $130.83 | $121.035 | $128.80 | 2.84M |
| Sep 8, 2026 | $124.78 | $127.42 | $121.38 | $124.89 | 1.61M |
| Sep 4, 2026 | $126.00 | $128.235 | $125.62 | $126.29 | 1.8M |
| Sep 3, 2026 | $126.70 | $127.09 | $124.05 | $126.68 | 1.89M |
| Sep 2, 2026 | $121.11 | $126.79 | $121.11 | $126.63 | 2M |
| Sep 1, 2026 | $121.95 | $122.19 | $119.5206 | $121.51 | 1.42M |
| Aug 31, 2026 | $118.68 | $122.71 | $117.51 | $121.82 | 2.39M |
| Aug 28, 2026 | $120.11 | $120.66 | $117.15 | $118.54 | 1.98M |
| Aug 27, 2026 | $124.67 | $126.10 | $121.21 | $121.39 | 1.06M |
| Aug 26, 2026 | $122.89 | $125.59 | $121.64 | $124.39 | 1.98M |
| Aug 25, 2026 | $124.65 | $127.18 | $122.865 | $123.89 | 2.37M |
| Aug 24, 2026 | $125.03 | $126.11 | $122.83 | $123.98 | 1.34M |
| Aug 21, 2026 | $125.22 | $127.20 | $124.82 | $125.77 | 1.12M |
| Aug 20, 2026 | $128.36 | $130.27 | $124.60 | $125.08 | 1.76M |
| Aug 19, 2026 | $129.85 | $131.10 | $127.42 | $130.66 | 1.49M |
| Aug 18, 2026 | $128.07 | $128.93 | $126.39 | $128.46 | 1.27M |
Latest INSM news
The latest Smart Investors Daily articles mentioning INSM.
Stock researchCompany · Overview
INSM research
Overview
Company profile and research snapshot.
Company profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $226.67
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Roth Capital | Buy | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 10, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Evercore ISI Group | Outperform | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.